Wockhardt says FDA inspected US unit in March quarter

Tags: Companies
The US Food and Drug Administration (FDA) has made some observations about the production process of the US unit of Indian generic drugmaker Wockhardt Ltd, the company said on Tuesday.

The FDA last year banned Wockhardt's two Indian units from exporting to the United States, its biggest market, citing quality lapses in the manufacturing process.

Managing Director Murtaza Khorakiwala told an analysts briefing the FDA had inspected the company's Chicago-based Morton Grove Pharmaceuticals unit, which accounts for more than 50 percent of its sales in the United States, in the March quarter. He did not give further details.

"It's difficult to say what kind of position the FDA will take but according to us the inspection was not a very negative inspection," Khorakiwala said.

Wockhardt on Monday reported a 78 percent drop in net profit for the March quarter, as it continues to reel under the U.S. and U.K. import bans due to manufacturing quality lapses.

In November, the U.S. Food and Drug Administration (FDA) issued an import alert, effectively a ban, against Wockhardt's Chikalthana plant in western India. The FDA had imposed a ban on the company's Waluj plant in May.

EDITORIAL OF THE DAY

  • Reservations, along with economic subsidies, must go to get India moving

    A young man, in his early twenties, starts an agitation demanding reservation for the community he represents.

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

Sarthak Raychaudhuri

vice-president, HR, Asia South Whirlpool of India

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

TODAY'S COLUMNS

Urs Schoettli

The China story isn’t over yet

China’s financial markets are currently in the eye of a ...

Anuja Sharma

Love yourself to love others

“There are two basic motivating forces: fear and love. When ...

Gautam Gupta

It's a 'blog eat blog' world out there

Let me tell you, fashion journalism has truly taken the ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture